Dagliflozin and saxagliptin are different mechanisms of hypoglycemic drugs, can be taken at the same time, play a synergistic role in hypoglycemia, should be used under the guidance of a doctor. Dagliflozin is a sodium-glucose co-transporter protein 2 inhibitor, which can inhibit the reabsorption of glucose in the renal tubules and increase urinary excretion of glucose to play a hypoglycemic role. This drug is contraindicated in patients with a history of hypersensitivity to this drug, severe renal insufficiency and dialysis patients. Adverse reactions such as hypovolemia, acute kidney injury and pyelonephritis may occur during use. Saxagliptin is a dipeptidyl peptidase-4 inhibitor, which stimulates insulin secretion to control blood glucose and reduces glucagon secretion from pancreatic alpha cells. The drug should not be used in people with a history of severe allergy to this drug. Adverse reactions during use include upper respiratory tract infections and headaches. When one hypoglycemic agent does not meet the blood glucose target, a combination of two or even three agents with different mechanisms of action may be used, as well as insulin. Specific drug regimens should be chosen under the guidance of a physician.